Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
Korean Journal of Ophthalmology
;
: 177-180, 2014.
Artículo
en Inglés
| WPRIM
| ID: wpr-147472
ABSTRACT
Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior. A 32-year-old female diagnosed with herpetic keratoconjunctivitis with refractory corneal NV despite two previous subconjunctival and intrastromal bevacizumab injections, received two subconjunctival and intrastromal ranibizumab injections. Six months postoperatively, there was significant regression of the neovascular area and vessel caliber. Here, the authors report a case of improvement in corneal NV with subconjunctival and intrastromal ranibizumab injections, which was previously refractory to bevacizumab injection. The findings may suggest a new prospect in treating corneal NV.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Agudeza Visual
/
Queratitis Herpética
/
Neovascularización de la Córnea
/
Conjuntiva
/
Sustancia Propia
/
Inhibidores de la Angiogénesis
/
Inyecciones Intraoculares
/
Anticuerpos Monoclonales Humanizados
Límite:
Adulto
/
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Korean Journal of Ophthalmology
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS